Neurogene Inc. Impairment of Long-Lived Assets Held-for-use
Neurogene Inc. (NGNE) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2023-11-14
- Neurogene Inc. impairment of long-lived assets held-for-use for the quarter ending 2023-09-30 was $0.00.
- Neurogene Inc. impairment of long-lived assets held-for-use for the quarter ending 2023-06-30 was $0.00.
- Neurogene Inc. impairment of long-lived assets held-for-use for the quarter ending 2023-03-31 was $3.40M.
- Neurogene Inc. impairment of long-lived assets held-for-use for the quarter ending 2022-09-30 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 1 month | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 3 month as first filed | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month |
|---|---|---|---|---|---|
| 2023-09-30 | $0.00 10-Q · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $3.42M 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-10 | $3.42M 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $3.40M 10-Q · filed 2023-11-14 | $3.40M 10-Q · filed 2023-11-14 | $3.42M 10-Q · filed 2023-05-08 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |